Avalo Therapeutics, Inc.
AVTXNASDAQHealthcare● Active
$14.86
+$0.10(+0.64%)
Market Cap$167774108
P/E Ratio—
52W High$24.27
52W Low$4.46
Avalo Therapeutics, Inc. (AVTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVTX · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($78.26M) | ($35.13M) | ($31.54M) | ($41.66M) | ($84.38M) |
| Depreciation & Amort. | $0.34M | $0.17M | $0.16M | $0.17M | $1.66M |
| Stock-Based Comp. | $13.62M | $5.85M | $3.48M | $7.55M | $8.17M |
| Change in Working Capital | $3.84M | ($4.71M) | ($9.24M) | ($0.06M) | $2.84M |
| Net Cash from Operations | ($51.46M) | ($49.06M) | ($30.68M) | ($26.75M) | ($70.89M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | ($0.16M) | ($0.10M) | ($0.11M) |
| Purchases of Investments | ($113.72M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $31.31M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($81.72M) | $0.36M | ($0.13M) | ($0.10M) | ($0.11M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | ($21.24M) | ($14.81M) | $32.90M |
| Net Cash from Financing | $14.59M | $175.85M | $25.04M | ($14.70M) | $106.76M |
| Free Cash Flow | |||||
| Free Cash Flow | ($51.46M) | ($49.06M) | ($30.84M) | ($26.85M) | ($71.00M) |
| FCF Margin %(computed) | — | — | — | -148.72% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Avalo Therapeutics, Inc. data
About Avalo Therapeutics, Inc. (AVTX) Cash Flow Statement
Avalo Therapeutics, Inc. generated operating cash flow of ($0.05B) and free cash flow of ($0.05B) for 2025 — a FCF margin of -87216.95%. Capital expenditure was $0.00B.
Frequently asked questions
AVTX · 4 questionsAvalo Therapeutics, Inc. generated free cash flow of ($0.05B) for 2025, down 4.9% year-over-year.
AVTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15